NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Edit:

Yes, I was lazy and didn’t use a graphic arts editor. However, now consider, in the Car-T trial, that arm 5 was:

1. A little bit younger than arms one plus arm two.
2. Had a little less actual GBM.
3. Had 15% more Grade 3 gliomas.
4. Had a 90 KPS average (but arm 1+2 had 80 KPS)

Then notice the real comparison.

Arm 1+2 had 6.9 months median survival for actual rGBM whereas Arm 5 had 10.2 median months for actual rGBM.

So it makes sense they are going for arm 5 in the next (phase 2) trial.